Latest Commercial Operations News

First Graphene Limited has reported a landmark quarter with a 156% surge in customer cash receipts and a major industrial-scale production of graphene-enhanced cement, signalling a pivotal step in commercialising graphene across multiple sectors.

InteliCare Holdings has advanced its aged care technology deployments and is close to appointing a new CEO, signalling a pivotal growth phase. The company also reported progress in commercial talks and product enhancements.

Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.

Alpha HPA Limited has raised A$225 million in a fully underwritten placement to fund the commercialisation of Stage 2 of its High Purity Alumina project, with strong backing from the National Reconstruction Fund Corporation. This capital injection positions the company to become the world’s largest single-site HPA manufacturer, supporting critical semiconductor supply chains.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Sea Forest Limited has exceeded its breakeven target for its methane-reducing feed additive SeaFeed™, securing commitments for over 118,000 cattle and expanding commercial trials with major industry partners.

Simble Solutions reported steady cash flow and operational growth in Q4 FY25, alongside a strategic acquisition and capital raise to bolster its energy intelligence offerings.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

1414 Degrees has returned to trading on the ASX following a significant capital raise involving 44 million new shares issued to US institutional investor Lind Global Fund II. This move marks a key step in the company’s ongoing funding strategy to support its renewable energy technologies.

Singular Health Group has advanced its U.S. commercial footprint with the deployment of 500 new licences under its PNS contract and secured FDA clearance for its cloud-based 3DICOM MD® platform, positioning the company for significant growth.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Genesis Energy has reported a robust second-quarter performance for FY26, underpinned by strong hydro generation and record-low thermal output, prompting an upward revision of its full-year earnings guidance. The company’s strategic focus on portfolio flexibility and renewable projects continues to drive margin quality and operational progress.